Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp has demonstrated robust financial performance, with revenue reflecting a significant 30% year-over-year increase, driven largely by episodic managed services contracts. The company has also provided optimistic guidance for 2025, indicating revenue visibility of over 85% and an expected growth range of 13-17%, surpassing pre-report consensus estimates. Furthermore, the positive EBITDA outlook, projected between $14.5 million and $17.5 million, coupled with operational efficiencies suggested by a stable revenue run-rate linked to current headcount, bolsters the company's potential for continued margin expansion and revenue growth in the healthcare digital messaging market.

Bears say

The financial performance of OptimizeRx has shown signs of instability, with declining revenue growth that raises concerns about its ability to maintain market share in the competitive healthcare technology landscape. Additionally, the increasing operational costs associated with delivering their cloud-based solutions may pressure profit margins, limiting the company's financial flexibility. Furthermore, the reliance on pharmaceutical companies for revenue may expose OptimizeRx to market volatility and regulatory changes, further contributing to an unfavorable outlook.

OptimizeRx Corp (OPRX) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 4 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.